Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
SBAR II: Application of SBAR01:14

SBAR II: Application of SBAR

4.3K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

133
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
133
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

162
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
162
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

232
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
232

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How can I select the right thyroid hormone formulation for my patient with hypothyroidism?

Cleveland Clinic journal of medicine·2025
Same author

An Integrated Interprofessional Continuing Medical Education and Quality Improvement Initiative to Address Cardiovascular and Renal Risk in Patients with Type 2 Diabetes in Community-Based Primary Care Practices.

Journal of CME·2025
Same author

Impact of the Addition of Beta-Hydroxybutyrate in the 72-Hour Fast Protocol on Hospitalization Duration: A Quality Improvement Report.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2025
Same author

Lymphedema vs lipedema: Similar but different.

Cleveland Clinic journal of medicine·2024
Same author

Association of Metformin, Dipeptidyl Dipeptidase-4 Inhibitors, and Insulin with Coronavirus Disease 2019-Related Hospital Outcomes in Patients with Type 2 Diabetes.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2023
Same author

Association between first-line monotherapy with metformin and the risk of atrial fibrillation (AMRAF) in patients with type 2 diabetes.

Journal of diabetes and its complications·2022

Related Experiment Video

Updated: May 29, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.6K

Hypoglycemia after bariatric surgery: Management updates.

Anira Iqbal1, Vinni Makin2

  • 1Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, OH aniraiqbal93@gmail.com.

Cleveland Clinic Journal of Medicine
|February 3, 2025
PubMed
Summary

Bariatric surgery can improve obesity-related conditions but may cause hypoglycemia. This article reviews current and emerging treatments for post-bariatric surgery hypoglycemia (PBH), a condition lacking approved medications.

More Related Videos

Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

6.5K
A Murine Model of Vertical Sleeve Gastrectomy
06:47

A Murine Model of Vertical Sleeve Gastrectomy

Published on: December 18, 2017

11.1K

Related Experiment Videos

Last Updated: May 29, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.6K
Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

6.5K
A Murine Model of Vertical Sleeve Gastrectomy
06:47

A Murine Model of Vertical Sleeve Gastrectomy

Published on: December 18, 2017

11.1K

Area of Science:

  • Metabolic Surgery
  • Endocrinology
  • Gastroenterology

Background:

  • Bariatric surgery offers significant health benefits for patients with obesity, including remission of type 2 diabetes and hypertension.
  • A notable complication is post-bariatric surgery hypoglycemia (PBH), which can manifest months or years after the procedure.
  • Currently, no specific medications are FDA-approved for managing PBH.

Purpose of the Study:

  • To review the available and investigational treatment options for post-bariatric surgery hypoglycemia.
  • To provide an overview of therapeutic strategies for this challenging complication.

Main Methods:

  • Literature review of studies on PBH management.
  • Analysis of current clinical guidelines and ongoing research.

Main Results:

  • Discussion of pharmacologic and non-pharmacologic interventions.
  • Highlighting emerging therapies under investigation for PBH.

Conclusions:

  • Effective management of PBH requires a comprehensive approach.
  • Further research is needed to develop approved and targeted therapies for PBH.